Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

How Many H. pylori Positive Patients Can Be Eradicated with Two Consecutive Regimens Proposed by the Maastricht Consensus Rules? (CROSBI ID 550197)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Katicic, Miroslava ; Filipec-Kanizaj, Tajana ; Mrzljak, Anna ; Prskalo, Marija ; Ticak, Mirjana ; Skurla, Bruno ; Naumovski-Mihalic, Slavica Sabaric, Branka ; Colic-Cvrlje, Vesna How Many H. pylori Positive Patients Can Be Eradicated with Two Consecutive Regimens Proposed by the Maastricht Consensus Rules? // Helicobacter (Cambridge, Mass.) / Graham, David, J (ur.). 2008. str. 460-460

Podaci o odgovornosti

Katicic, Miroslava ; Filipec-Kanizaj, Tajana ; Mrzljak, Anna ; Prskalo, Marija ; Ticak, Mirjana ; Skurla, Bruno ; Naumovski-Mihalic, Slavica Sabaric, Branka ; Colic-Cvrlje, Vesna

engleski

How Many H. pylori Positive Patients Can Be Eradicated with Two Consecutive Regimens Proposed by the Maastricht Consensus Rules?

Background: All three Maastricht Consensuses suggest same drags combination for treatment H.pylori infection ; proton pump inhibitor(PPI) and two of three antibiotics: Amoxicillin(A), Clarithromycin(C), Metronidazole(M), and for resistant H.pylori strains quadruple regimen consisting of PPI, Bismuth(B), M and Tetracycline(T).From 1996 we treated our patients according this suggestion. Aim: To calculate H. pylori eradication rates which can be achieved by such two steps of treatment regimens. Methods: 1067 consecutive H.pylori positive patients received first one of three regimens(PPI+C+M, PPI+A+C, PPI+A+M) ; during second treatment we replaced M with C, and vice versa or used quadruple regimen(PPI+B+M+T). Success rate was calculated by intention to treat(ITT) and per protocol(PP) analyses. H.pylori eradication was assessed by histology or UBT. Results: After first treatment 797 patients were eradicated and 18 patients were lost (ITT-74.7%, PP-76, 0% ; ) ; Eradication rate with PPI+M+C was 78, 9%, with PPI+A+C 76, 0%, and with PPI+A+M 74, 1%. Remaining 252 H.pylori+ve patients were treated according above task. Infection was eradicated in 142 patients and 40 patients were lost. (ITT-56, 3%, PP-67, 0%). Eradication was achieved with PPI+M+C in 68, 2%, with PPI+A+C in 69, 9%, with PPI+A+M in 60, 0%, and with PPI+B+M+T in 84, 2%. Summary, from 1067 patients included in treatment we eradicated H.pylori infection in 997 patients, lost from study 58 patients, and 70 patients remained positive (ITT-88, 0% ; PP-93, 4%). Primary resistance to clarithromycin was 8.4 % and for metronidazol 33.5 %. Conclusion: Two consecutive treatments proposed by all three Maastricht consensuses, achieved enough high H.pylori eradication rates in Republic Croatia with still relative low primary resistance to Clarithromycin.

Helicobacter; Maastricht consensus

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

460-460.

2008.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Helicobacter (Cambridge, Mass.)

Graham, David, J

Houston (TX): Wiley-Blackwell

1083-4389

Podaci o skupu

XXI International Workshop on Helicobacter and related bacteria in chronic digestive inflammation

poster

18.09.2008-20.09.2008

Riga, Latvija

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost